Advertisement

Neuroscience Bulletin

, Volume 34, Issue 2, pp 270–282 | Cite as

Radio Electric Asymmetric Conveyer Technology Modulates Neuroinflammation in a Mouse Model of Neurodegeneration

  • Maria Antonietta Panaro
  • Alessandra Aloisi
  • Giuseppe Nicolardi
  • Dario Domenico Lofrumento
  • Francesco De Nuccio
  • Velia La Pesa
  • Antonia Cianciulli
  • Rosaria Rinaldi
  • Rosa Calvello
  • Vania Fontani
  • Salvatore Rinaldi
Original Article

Abstract

In this study, the effects of Radio Electric Asymmetric Conveyer (REAC), a non-invasive physical treatment, on neuroinflammatory responses in a mouse model of parkinsonism induced by intoxication with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), were investigated in vivo. We found that the REAC tissue optimization treatment specific for neuro-regenerative purposes (REAC TO-RGN-N) attenuated the inflammatory picture evoked by MPTP-induced nigro-striatal damage in mice, decreasing the levels of pro-inflammatory molecules and increasing anti-inflammatory mediators. Besides, there was a significant reduction of both astrocyte and microglial activation in MPTP-treated mice exposed to REAC TO-RGN-N. These results indicated that REAC TO-RGN-N treatment modulates the pro-inflammatory responses and reduces neuronal damage in MPTP-induced parkinsonism.

Keywords

Parkinson’s disease Neurodegeneration Neuroinflammation REAC TO-RGN-N treatment 

Notes

Acknowledgements

We are grateful to Mr. Diego Mangiullo for technical assistance in animal cage assembly. This work was partially supported by a Fondazione Umberto Veronesi 2011 grant to RR, by a grant from the University of Bari (Fondi di Ateneo 2014), and by a grant from the University of Salento (Fondi di Ateneo 2014).

Compliance with Ethical Standards

Conflict of interest

Salvatore Rinaldi and Vania Fontani are the inventors of REAC technology. They are also founders of the company that produces REAC technology.

References

  1. 1.
    González-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999, 22: 219–240.CrossRefPubMedGoogle Scholar
  2. 2.
    Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang K-C, Wegiel J. Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease. Neurobiol Aging 2004, 25: 663–674.CrossRefPubMedGoogle Scholar
  3. 3.
    Chen Z, Zhong C. Oxidative stress in Alzheimer’s disease. Neurosci Bull 2014, 30: 271–281.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Su F, Bai F, Zhang Z. Inflammatory cytokines and Alzheimer’s disease: a review from the perspective of genetic polymorphisms. Neurosci Bull 2016, 32: 469–480.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Eder C. Regulation of microglial behavior by ion channel activity. J Neurosci Res 2005, 81: 314–321.CrossRefPubMedGoogle Scholar
  6. 6.
    Jurgens HA, Johnson RW. Dysregulated neuronal-microglial cross-talk during aging, stress and inflammation. Exp Neurol 2012, 233: 40–48.CrossRefPubMedGoogle Scholar
  7. 7.
    Kingwell K. Neurodegenerative disease: Microglia in early disease stages. Nat Rev Neurol 2012, 8: 475.CrossRefPubMedGoogle Scholar
  8. 8.
    Yuan H, Zheng JC, Liu P, Zhang SF, Xu JY, Bai LM. Pathogenesis of Parkinson’s disease: oxidative stress, environmental impact factors and inflammatory processes. Neurosci Bull 2007, 23: 125–130.CrossRefPubMedGoogle Scholar
  9. 9.
    Yuan H, Zhang ZW, Liang LW, Shen Q, Wang XD, Ren SM, et al. Treatment strategies for Parkinson’s disease. Neurosci Bull 2010, 26: 66.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, Breloer M, et al. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep 2013, 3: 1393.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Lofrumento DD, Saponaro C, Cianciulli A, De Nuccio F, Mitolo V, Nicolardi G, et al. MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. Neuroimmunomodulation 2011, 18: 79–88.CrossRefPubMedGoogle Scholar
  12. 12.
    Panaro MA, Lofrumento DD, Saponaro C, De Nuccio F, Cianciulli A, Mitolo V, et al. Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson’s-like disease. Immunopharmacol Immunotoxicol 2008, 30: 729–740.CrossRefPubMedGoogle Scholar
  13. 13.
    Collodel G, Fioravanti A, Pascarelli NA, Lamboglia A, Fontani V, Maioli M, et al. Effects of regenerative radioelectric asymmetric conveyer treatment on human normal and osteoarthritic chondrocytes exposed to IL-1B: A biochemical and morphological study. Clin Interv Aging 2013, 8: 309–316.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Maioli M, Rinaldi S, Santaniello S, Castagna A, Pigliaru G, Gualini S, et al. Radiofrequency energy loop primes cardiac, neuronal, and skeletal muscle differentiation in mouse embryonic stem cells: A new tool for improving tissue regeneration. Cell Transplant 2012, 21: 1225–1233.CrossRefPubMedGoogle Scholar
  15. 15.
    Rinaldi S, Maioli M, Santaniello S, Castagna A, Pigliaru G, Gualini S, et al. Regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study. Clin Interv Aging 2012, 7: 191–194.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Maioli M, Rinaldi S, Santaniello S, Castagna A, Pigliaru G, Delitala A, et al. Radioelectric asymmetric conveyed fields and human adipose-derived stem cells obtained with a nonenzymatic method and device: a novel approach to multipotency. Cell Transplant 2014, 23: 1489–1500.CrossRefPubMedGoogle Scholar
  17. 17.
    Mura M, Castagna A, Fontani V, Rinaldi S. Preliminary pilot fMRI study of neuropostural optimization with a noninvasive asymmetric radioelectric brain stimulation protocol in functional dysmetria. Neuropsychiatr Dis Treat 2012, 8: 149–154.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Rinaldi S, Fontani V, Castagna A. Brain activity modification produced by a single radioelectric asymmetric brain stimulation pulse: a new tool for neuropsychiatric treatments. Preliminary fMRI study. Neuropsychiatr Dis Treat 2011, 7: 649–654.CrossRefPubMedGoogle Scholar
  19. 19.
    Rinaldi S, Fontani V, Moretti E, Rosettani B, Aravagli L, Saragò G, et al. A new approach on stress-related depression & anxiety: Neuro-Psycho- Physical-Optimization with Radio Electric Asymmetric-Conveyer. Indian J Med Res 2010, 132: 189–194.PubMedGoogle Scholar
  20. 20.
    Rinaldi S, Fontani V, Aravagli L, Margotti ML. Psychological and symptomatic stress-related disorders with radio-electric treatment: psychometric evaluation. Stress Heal 2010, 26: 350–358.CrossRefGoogle Scholar
  21. 21.
    Rinaldi S, Fontani V, Mannu P, Castagna A. Social anxiety disorder: radio electric asymmetric conveyor brain stimulation versus sertraline. Patient Prefer Adherence 2011, 5: 581–586.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Rinaldi S, Fontani V, Aravagli L, Mannu P, Castagna A, Lotti M. Noninvasive radioelectric asymmetric brain stimulation in the treatment of stress-related pain and physical problems: psychometric evaluation in a randomized, single-blind placebo-controlled, naturalistic study. Int J Gen Med 2011, 4: 681–686.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Rinaldi S, Mannu P, Fontani V, Castagna A. Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor. Neuropsychiatr Dis Treat 2011, 7: 373–379.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Olivieri EB, Vecchiato C, Ignaccolo N, Mannu P, Castagna A, Aravagli L, et al. Radioelectric brain stimulation in the treatment of generalized anxiety disorder with comorbid major depression in a psychiatric hospital: a pilot study. Neuropsychiatr Dis Treat 2011, 7: 449–455.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Rinaldi S, Fontani V, Aravagli, Lotti M, Castagna A, Piero Mannu. Neuropsychophysical optimization by REAC technology in the treatment of: sense of stress and confusion. Psychometric evaluation in a randomized, single blind, sham-controlled naturalistic study. Patient Prefer Adherence 2012, 6: 195–199.Google Scholar
  26. 26.
    Rinaldi S, Mannu P, Fontani V, Castagna A. Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease. Clin Interv Aging 2011, 6: 207–211.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Olazarán J, González B, López-Álvarez J, Castagna A, Osa-Ruiz E, Herrero-Cano V, et al. Motor effects of REAC in advanced Alzheimer’s disease: results from a pilot trial. J Alzheimers Dis 2013, 36: 297–302.PubMedGoogle Scholar
  28. 28.
    Luca L, Alessandro G, Sandra S, Antonio BV, Mercedes F, Matteo LM, et al. REAC technology modifies pathological neuroinflammation and motor behaviour in an Alzheimer’s disease mouse model. Sci Rep 2016, 6: 35719.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Maioli M, Rinaldi S, Santaniello S, Castagna A, Pigliaru G, Delitala A, et al. Anti-senescence efficacy of radio-electric asymmetric conveyer technology. Age (Omaha) 2014, 36: 9–20.CrossRefGoogle Scholar
  30. 30.
    Maioli M, Rinaldi S, Santaniello S, Castagna A, Pigliaru G, Gualini S, et al. Radio electric conveyed fields directly reprogram human dermal skin fibroblasts toward cardiac, neuronal, and skeletal muscle-like lineages. Cell Transplant 2013 22: 1227–1235.CrossRefPubMedGoogle Scholar
  31. 31.
    Maioli M, Rinaldi S, Migheli R, Pigliaru G, Rocchitta G, Santaniello S, et al. Neurological morphofunctional differentiation induced by REAC technology in PC12. A neuro protective model for Parkinson’s disease. Sci Rep 2015, 5: 10439.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Rinaldi S, Maioli M, Pigliaru G, Castagna A, Santaniello S, Basoli V, et al. Stem cell senescence: Effects of REAC technology on telomerase-independent and telomerase-dependent pathways. Sci Rep 2014, 4: 6373.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Rinaldi S, Mura M, Castagna A, Fontani V. Long-lasting changes in brain activation induced by a single REAC technology pulse in Wi-Fi bands. Randomized double-blind fMRI qualitative study. Sci Rep 2014, 4: 5668.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Zippo AG, Rinaldi S, Pellegata G, Caramenti GC, Valente M, Fontani V, et al. Electrophysiological effects of non-invasive Radio Electric Asymmetric Conveyor (REAC) on thalamocortical neural activities and perturbed experimental conditions. Sci Rep 2015, 5: 18200.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc 2007, 2: 141–151.CrossRefPubMedGoogle Scholar
  36. 36.
    Panaro MA, Carofiglio V, Calvello C, Aloisi A, Rinaldi R, Nicolardi G, et al. Modulation of pro-inflammatory response in a mouse model of Parkinson’s disease by non-invasive physical approach: preliminary evaluation. Proc 2015 IEEE 15th Mediterr Microw Symp 2015: 1–4.Google Scholar
  37. 37.
    Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46: 598–605.CrossRefPubMedGoogle Scholar
  38. 38.
    Miller KM, Okun MS, Marsiske M, Fennell EB, Bowers D. Startle reflex hyporeactivity in Parkinson’s disease: An emotion-specific or arousal-modulated deficit? Neuropsychologia 2009, 47: 1917–1927.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 2003, 39: 889–909.CrossRefPubMedGoogle Scholar
  40. 40.
    McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord 2004, 10: S3–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Gao HM. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease. FASEB J 2003, 17: 1957–1959.CrossRefPubMedGoogle Scholar
  42. 42.
    Nagatsu T, Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson’s disease: possible implications of glial cells. J Neural Transm Suppl 2006, 71: 53–65.CrossRefGoogle Scholar
  43. 43.
    Panaro MA, Cianciulli A. Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson’s disease. Curr Pharm Des 2012, 18: 200–208.CrossRefPubMedGoogle Scholar
  44. 44.
    Doherty GH. Nitric oxide in neurodegeneration: potential benefits of non-steroidal anti-inflammatories. Neurosci Bull 2011, 27: 366–382.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Kurkowska-Jastrzębska I, Wrońska A, Kohutnicka M, Członkowski A, Członkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999, 156: 50–61.CrossRefPubMedGoogle Scholar
  46. 46.
    Nagatsu T, Mogi M, Ichinose H, Togari A. Cytokines in Parkinson’s disease. J Neural Transm Suppl 2000, 54: 143–151.Google Scholar
  47. 47.
    Mandel S, Weinreb O, Youdim MB. Using cDNA microarray to assess Parkinson’s disease models and the effects of neuroprotective drugs. Trends Pharmacol Sci 2003, 24: 184–191.CrossRefPubMedGoogle Scholar
  48. 48.
    Knott C, Stern G, Wilkin GP. Inflammatory regulators in Parkinson’s disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 2000, 16: 724–739.CrossRefPubMedGoogle Scholar
  49. 49.
    Bal-Price A, Brown GC. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 2001, 21: 6480–6491.PubMedGoogle Scholar
  50. 50.
    Bal-Price A, Matthias A, Brown GC. Stimulation of the NADPH oxidase in activated rat microglia removes nitric oxide but induces peroxynitrite production. J Neurochem 2002, 80: 73–80.CrossRefPubMedGoogle Scholar
  51. 51.
    Broom L, Marinova-Mutafchieva L, Sadeghian M, Davis JB, Medhurst AD, Dexter DT. Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease. Free Radic Biol Med 2011, 50: 633–640.CrossRefPubMedGoogle Scholar
  52. 52.
    Gahm C, Holmin S, Wiklund PN, Brundin L, Mathiesen T. Neuroprotection by selective inhibition of inducible nitric oxide synthase after experimental brain contusion. J Neurotrauma 2006, 23: 1343–1354.CrossRefPubMedGoogle Scholar
  53. 53.
    Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, et al. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 2007, 100: 1375–1386.CrossRefPubMedGoogle Scholar
  54. 54.
    Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson’s disease. Exp Neurol 2007, 205: 295–312.CrossRefPubMedGoogle Scholar
  55. 55.
    Molina-Holgado F, Grencis R, Rothwell NJ. Actions of exogenous and endogenous IL-10 on glial responses to bacterial LPS/cytokines. Glia 2001, 33: 97–106.CrossRefPubMedGoogle Scholar
  56. 56.
    Cianciulli A, Dragone T, Calvello R, Porro C, Trotta T, Lofrumento DD, et al. IL-10 plays a pivotal role in anti-inflammatory effects of resveratrol in activated microglia cells. Int Immunopharmacol 2015, 24: 369–376.CrossRefPubMedGoogle Scholar
  57. 57.
    Stoll G, Jander S, Schroeter M. Cytokines in CNS disorders: neurotoxicity versus neuroprotection. J Neural Transm Suppl 2000, 59: 81–89.PubMedGoogle Scholar
  58. 58.
    Calvello R, Cianciulli A, Nicolardi G, De Nuccio F, Giannotti L, Salvatore R. Vitamin D treatment attenuates neuroinflammation and dopaminergic neurodegeneration in an animal model of Parkinson’s disease, Shifting M1 to M2 microglia responses. J Neuroimmune Pharmacol 2017, 12: 327–339.CrossRefPubMedGoogle Scholar
  59. 59.
    Dragone T, Cianciulli A, Calvello R, Porro C, Trotta T, Panaro MA. Resveratrol counteracts lipopolysaccharide-mediated microglial inflammation by modulating a SOCS-1 dependent signaling pathway. Toxicol In Vitro 2014, 28: 1126–1135.CrossRefPubMedGoogle Scholar
  60. 60.
    Lofrumento DD, Nicolardi G, Cianciulli A, De Nuccio F, La Pesa V, Carofiglio V, et al. Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson’s-like disease: Possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immun 2014, 20: 249–260.CrossRefPubMedGoogle Scholar
  61. 61.
    Qin H, Niyongere SA, Lee SJ, Baker BJ, Benveniste EN. Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes. J Immuno 2008, 181: 3167–3176.CrossRefGoogle Scholar
  62. 62.
    Sedeño-Monge V, Arcega-Revilla R, Rojas-Morales E, Santos-López G, Perez-García JC, Sosa-Jurado F, et al. Quantitative analysis of the suppressors of cytokine signaling 1 and 3 in peripheral blood leukocytes of patients with multiple sclerosis. J Neuroimmunol 2014, 273: 117–119.CrossRefPubMedGoogle Scholar
  63. 63.
    Guedes JR, Custodia CM, Silva RJ, de Almeida LP, Pedroso de Lima MC, Cardoso AL. Early miR-155 upregulation contributes to neuroinflammation in Alzheimer’s disease triple transgenic mouse model. Hum Mol Gene 2014, 23: 6286–6301.CrossRefGoogle Scholar
  64. 64.
    Mansell A, Smith R, Doyle SL, Gray P, Fenner JE, Crack PJ, et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006, 7: 148–155.CrossRefPubMedGoogle Scholar
  65. 65.
    Jung DY, Lee H, Jung BY, Ock J, Lee MS, Lee WH, et al. TLR4, but not TLR2, signals autoregulatory apoptosis of cultured microglia: a critical role of IFN-beta as a decision maker. J Immunol 2005, 174: 6467–6476.CrossRefPubMedGoogle Scholar
  66. 66.
    Liu HY, Chen CY, Hsueh YP. Innate immune responses regulate morphogenesis and degeneration: roles of Toll-like receptors and Sarm1 in neurons. Neurosci Bull 2014, 30: 645–654.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Trotta T, Porro C, Calvello R, Panaro MA. Biological role of Toll-like receptor-4 in the brain. J Neuroimmunol 2014, 268: 1–12.CrossRefPubMedGoogle Scholar
  68. 68.
    Letiembre M, Liu Y, Walter S, Hao W, Pfander T, Wrede A, et al. Screening of innate immune receptors in neurodegenerative diseases: A similar pattern. Neurobiol Aging 2009, 30: 759–768.CrossRefPubMedGoogle Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS and Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  • Maria Antonietta Panaro
    • 1
  • Alessandra Aloisi
    • 2
  • Giuseppe Nicolardi
    • 3
  • Dario Domenico Lofrumento
    • 3
  • Francesco De Nuccio
    • 3
  • Velia La Pesa
    • 4
  • Antonia Cianciulli
    • 1
  • Rosaria Rinaldi
    • 2
    • 5
    • 6
  • Rosa Calvello
    • 1
  • Vania Fontani
    • 7
    • 8
  • Salvatore Rinaldi
    • 7
    • 8
    • 9
  1. 1.Department of Biosciences, Biotechnologies and BiopharmaceuticsUniversity of BariBariItaly
  2. 2.CNR Institute for Microelectronics and MicrosystemsLecceItaly
  3. 3.Department of Biological and Environmental Sciences and Technologies, Section of Human AnatomyUniversity of SalentoLecceItaly
  4. 4.Neuropathology Unit, Institute of Experimental Neurology, Division of NeuroscienceIRCCS San Raffaele Scientific InstituteMilanItaly
  5. 5.Department of Mathematics and PhysicsUniversity of SalentoLecceItaly
  6. 6.CNR Institute of Nanoscience NESTPisaItaly
  7. 7.Department of Regenerative MedicineRinaldi Fontani InstituteFlorenceItaly
  8. 8.Research DepartmentRinaldi Fontani FoundationFlorenceItaly
  9. 9.IRF (Shanghai) Medical SciencesShanghaiChina

Personalised recommendations